Rigel Pharmaceuticals (FRA:RI2) OCF Margin %: 4.63% (As of Mar. 2026)

What is Rigel Pharmaceuticals OCF Margin %?

Rigel Pharmaceuticals FRA:RI2 +4.43% 78 OCF Margin % is 4.63% as of Mar. 2026. GuruFocus rates FRA:RI2 with a GF Score™ of 78/100 and a GF Value™ of €23.45. The stock has 8 warning signs investors should review. Among 959 Biotechnology companies, Rigel Pharmaceuticals ranks better than 87.49% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Rigel Pharmaceuticals's Cash Flow from Operations for the three months ended in Mar. 2026 was €2.4 Mil. Rigel Pharmaceuticals's Revenue for the three months ended in Mar. 2026 was €50.9 Mil. Therefore, Rigel Pharmaceuticals's OCF Margin % for the quarter that ended in Mar. 2026 was 4.63%.

As of today, Rigel Pharmaceuticals's current OCF Yield % is 12.03%.

The historical rank and industry rank for Rigel Pharmaceuticals's OCF Margin % or its related term are showing as below:

FRA:RI2' s OCF Margin % Range Over the Past 10 Years
Min: -1729.64 Med: -54.69 Max: 25.71
Current: 26.4

During the past 13 years, the highest OCF Margin % of Rigel Pharmaceuticals was 25.71%. The lowest was -1729.64%. And the median was -54.69%.

FRA:RI2's OCF Margin % is ranked better than
87.49% of 959 companies
in the Biotechnology industry
Industry Median: -66.52 vs FRA:RI2: 26.40

Rigel Pharmaceuticals OCF Margin % Related Terms

Rigel Pharmaceuticals OCF Margin % Historical Data

* Premium members only.

The historical data trend for Rigel Pharmaceuticals's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rigel Pharmaceuticals OCF Margin % Chart

Rigel Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

OCF Margin %

Get a 7-Day Free Trial

3.94

-61.34

-4.91

17.55

25.71

Rigel Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
OCF Margin %	Get a 7-Day Free Trial															-1.67	30.03	34.59	31.49	4.63

FRA:RI2 vs CBIO, TRAX, GYRE: OCF Margin % Comparison

For the Biotechnology subindustry, Rigel Pharmaceuticals's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rigel Pharmaceuticals OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rigel Pharmaceuticals's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Rigel Pharmaceuticals's OCF Margin % falls into.

Save Embed

78GF Score

Rigel Pharmaceuticals Inc FRA:RI2

OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Rigel Pharmaceuticals OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Rigel Pharmaceuticals's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin	=	Cash Flow from Operations (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	64.609	/	251.317
	=	25.71 %

Rigel Pharmaceuticals's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin	=	Cash Flow from Operations (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	2.357	/	50.878
	=	4.63 %

Frequently Asked Questions Learn more about OCF Margin % →

What does a OCF Margin % of 4.63% mean?

Rigel Pharmaceuticals (FRA:RI2) has a OCF Margin % of 4.63% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Rigel Pharmaceuticals and its competitors. According to the industry distribution chart, Rigel Pharmaceuticals ranks #120 out of 959 companies in the Biotechnology industry, placing it in the top 12.5%.

Is Rigel Pharmaceuticals' OCF Margin % too high?

Rigel Pharmaceuticals' current OCF Margin % is 4.63%. Based on the distribution chart, Rigel Pharmaceuticals ranks #120 out of 959 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Rigel Pharmaceuticals has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.

How does Rigel Pharmaceuticals' OCF Margin % compare to CBIO and TRAX?

According to the Biotechnology industry distribution chart, Rigel Pharmaceuticals ranks #120 out of 959 companies for OCF Margin %. This places Rigel Pharmaceuticals in the top 13% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good OCF Margin % for a Biotechnology company?

A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high OCF Margin % mean?

A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Rigel Pharmaceuticals and its competitors. Rigel Pharmaceuticals's current OCF Margin % is 4.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Rigel Pharmaceuticals stock overvalued right now?

Rigel Pharmaceuticals (FRA:RI2) has a current OCF Margin % of 4.63%. The stock's GF Value™ is €23.45, compared to a current price of €29.47 — trading 25.7% above its estimated fair value. The current OCF Margin % is 4.63%. Rigel Pharmaceuticals' overall GF Score™ is 78/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is OCF Margin % calculated?

OCF Margin % is calculated from a company's financial statements. For Rigel Pharmaceuticals (FRA:RI2), the current OCF Margin % is 4.63% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rigel Pharmaceuticals (FRA:RI2) Overvalued in 2026?

Based on GuruFocus' analysis, Rigel Pharmaceuticals stock appears to be overvalued. The current stock price of €29.47 is trading 25.7% above its estimated GF Value™ of €23.45.

Key valuation signals for FRA:RI2:

OCF Margin %: 4.63%
GF Value™: €23.45 vs. price of €29.47 (25.7% above fair value)
GF Score™: 78/100 with 8 warning signs

No single metric tells the full story. See the FRA:RI2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rigel Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies CBIO TRAX GYRE AGMB ARVN MDXG ASMB EIKN TECX ACHV VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges RIGL:USA

Address 611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080

Website https://www.rigel.com

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.

78GF Score

Get the complete analysis for FRA:RI2

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€29.47

Price

€23.45

GF Value

View FRA:RI2 Analysis

See OCF Margin % data for all stocks →